Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines | Eli Lilly and Company - Investors | Eli Lilly and Company investor.lilly.com Submitted by lillycom9342 on May 25, 2024 at 11:56 PM in business No comments 51
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company - Investors | Eli Lilly and Company investor.lilly.com Submitted by lillycom9342 on October 27, 2023 at 10:25 PM in business No comments 59
U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer | Eli Lilly and Company - Investors | Eli Lilly and Company investor.lilly.com Submitted by lillycom9342 on October 3, 2023 at 10:46 AM in business No comments 43